3种胆碱酯酶抑制剂与复方海蛇胶囊单用或联用治疗阿尔茨海默病的效果比较 点击下载
| 论文标题： | 3种胆碱酯酶抑制剂与复方海蛇胶囊单用或联用治疗阿尔茨海默病的效果比较 |
| 英文标题： | |
| 中文摘要： | 目的：比较3种胆碱酯酶抑制剂（ChEI）与复方海蛇胶囊单用或联用治疗阿尔茨海默病（AD）的效果。方法：将210例AD患者按照就诊顺序依次纳入多奈哌齐组、卡巴拉汀组、加兰他敏组、复方海蛇胶囊组、多奈哌齐+复方海蛇胶囊组、卡巴拉汀+复方海蛇胶囊组和加兰他敏+复方海蛇胶囊组，各30例。多奈哌齐组患者睡前给予盐酸多奈哌齐片5 mg（＜1个月）、10 mg（≥1个月），po，qd；卡巴拉汀组患者给予重酒石酸卡巴拉汀胶囊1.5 mg（＜1个月）、3.0 mg（≥1个月），po，bid；加兰他敏组患者给予氢溴酸加兰他敏片2 mg（＜2周）、4 mg（2～4周）、6 mg（＞4周），po，bid；复方海蛇胶囊组患者给予复方海蛇胶囊3粒，po，tid；多奈哌齐+复方海蛇胶囊组患者给予盐酸多奈哌齐片5 mg，po，qd +复方海蛇胶囊3粒，po，tid；卡巴拉汀+复方海蛇胶囊组患者给予重酒石酸卡巴拉汀胶囊1.5 mg，po，bid +复方海蛇胶囊3粒，po，tid；加兰他敏+复方海蛇胶囊组患者给予氢溴酸加兰他敏片4 mg，po，bid +复方海蛇胶囊3粒，po，tid。各组患者疗程均为3个月。观察各组患者治疗前后简易精神状态检查量表（MMSE）、AD痴呆评定量表（ADAS-cog）、日常生活活动能力量表（ADL）治疗后的副反应量表（TESS）评分，以及不良反应发生情况。结果：治疗前，各组患者的MMSE、ADAS-cog及ADL评分比较，差异均无统计学意义（P＞0.05）。治疗后，各组患者的MMSE、ADAS-cog及ADL评分均明显改善；ChEI联合复方海蛇胶囊的各组患者的MMSE评分均明显高于相应的ChEI单用组和复方海蛇胶囊组，而ADAS-cog、ADL评分均明显低于相应的ChEI单用组和复方海蛇胶囊组；复方海蛇胶囊单用或联用ChEI组的TESS评分均明显低于相应的ChEI单用组，且不良反应发生率明显低于ChEI单用组，差异均有统计学意义（P＜0.05）。结论：ChEI联合复方海蛇胶囊可有效改善AD患者的精神状态，提高其认知功能和生活活动能力，且安全性较高。 |
| 英文摘要： | OBJECTIVE： To observe the effects of Cholinesterase inhibitor combined with Compound haishe capsule on prognosis of patients with Alzheimer’s disease （AD）. METHODS： 210 AD patients were divided into donepezil group， rivastigmine group， galantamine group， Compound haishe capsule group， donepezil + Compound haishe capsule group， rivastigmine + Compound haishe capsule， and galantamine + Compound haishe capsule group， 30 cases in each group according to visiting order. Donepezil group received Donepezil hydrochloride tablet 5 mg （＜1 month） before going to bed， 10 mg （≥1 month）， po， qd； rivastigmine group received Rivastigmine hydrogen tartrate capsule 1.5 mg （＜1 month） before going to bed， 3.0 mg （≥1 month）， po， bid； galantamine group received Galantamine hydrobromide tablet 2 mg （＜2 weeks）， 4 mg （2-4 weeks）， 6 mg （＞4 weeks）， po， bid； Compound haishe capsule received Compound haishe capsule 3 casuples， po， tid； donepezil + Compound haishe capsule group received Donepezil hydrochloride tablet 5 mg， po， qd + Compound haishe capsule 3 casuples， po， tid； galantamine + Compound haishe capsule group received Rivastigmine hydrogen tartrate capsule 1.5 mg， po， bid + Compound haishe capsule 3 casuples， po， tid； galantamine + Compound haishe capsule group received Galantamine hydrobromide tablet 4 mg， po， bid + Compound haishe capsule 3 casuples， po， tid. The treatment course for all groups was 3 months. Mini-mental state examination （MMSE）， AD dementia rating scale （ADAS-cog） and ability of daily life （ADL score） before and after treatment， and TESS score after treatment in all groups were observed， and the occurrence of ADR was observed. RESULTS： There was no statistical significance in MMSE， ADAS-cog and ADL score between 2 groups before treatment （P＞0.05）.After treatment， MMSE， ADAS-cog and ADL score in all groups were obviously improved； MMSE scores in ChEI combined with Compound haishe capsule groups were obviously higher than appropriate ChEI alone groups and Compound haishe capsule alone group， ADAS-cog and ADL scores were obviously lower than appropriate ChEI alone groups and Compound haishe capsule alone group； TESS scores incidence of adverse reactions in Compound haishe capsule alone group or combined with ChEI groups were obviously lower than appropriate ChEI alone groups and Compound haishe capsule group， the differences were statistically significant （P＜0.05）. CONCLUSIONS： ChEI combined with Compound haishe capsule can effectively improve the mental state of AD patients， cognitive function and life activity， with higher safety. |
| 期刊： | 2016年第27卷第26期 |
| 作者： | 朱黎，成旭东，安燕芳，赵辛欣，李燕楚 |
| 英文作者： | ZHU Li，CHENG Xudong，AN Yanfang，ZHAO Xinxin，LI Yanchu |
| 关键字： | 阿尔茨海默病；复方海蛇胶囊；胆碱酯酶抑制剂；多奈哌齐；卡巴拉汀；加兰他敏 |
| KEYWORDS： | Alzheimer’s disease； Compound haishe capsule； Cholinesterase inhibitors； Donepezil； Rwastigmine； Galantamin |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！